Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
5.59% $52.33
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 527.03 mill |
EPS: | -0.0700 |
P/E: | -747.57 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 48.29 mill |
Avg Daily Volume: | 0.594 mill |
RATING 2024-03-27 |
---|
S- |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Buy | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -747.57 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-127.17x |
Company: PE -747.57 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.75 (-92.83%) $-48.58 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 50.54 - 54.12 ( +/- 3.41%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Colangelo Dominick | Buy | 17 500 | Stock Option (Right to Buy) |
2024-03-14 | Colangelo Dominick | Buy | 17 500 | Stock Option (Right to Buy) |
2024-03-14 | Colangelo Dominick | Buy | 17 500 | Common Stock |
2024-03-14 | Colangelo Dominick | Sell | 17 500 | Common Stock |
2024-03-13 | Colangelo Dominick | Sell | 17 500 | Common Stock |
INSIDER POWER |
---|
65.48 |
Last 98 transactions |
Buy: 831 070 | Sell: 174 197 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $52.33 (5.59% ) |
Volume | 0.554 mill |
Avg. Vol. | 0.594 mill |
% of Avg. Vol | 93.22 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $45.62 | N/A | Active |
---|
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.